Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Updates on Approved CAR-Ts for Lymphomas

Moffitt Cancer Center

J. Chavez

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

ASH 2024 Review: Key Updates in Non-Hodgkin Lymphoma

Cleveland Clinic Taussig Cancer Institute

P. Caimi

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Infectious Disease Perspective of CAR T-Cell Therapy

Moffitt Cancer Center

A. Baluch

ASH 2024 Insights: Odronextamab in R/R DLBCL Post-CAR T-Cell Progres…

2024 ASH Annual Meeting Insights Hub

M. Matasar

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

Tafasitamab + Lenalidomide in R/R DLBCL: Updated Results From the L-…

David Bond

R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?

Moffitt Cancer Center

J. Chavez

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith